James D Mckay

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3506103/publications.pdf

Version: 2024-02-01

8 papers

1,979 citations

1163117 8 h-index 1588992 8 g-index

8 all docs 8 docs citations

8 times ranked 1984 citing authors

#	Article	IF	CITATIONS
1	Interleukinâ€6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to diseaseâ€modifying antirheumatic drugs: The tocilizumab in combination with traditional diseaseâ€modifying antirheumatic drug therapy study. Arthritis and Rheumatism, 2008, 58, 2968-2980.	6.7	752
2	A phase II, randomized, doubleâ€blind, placeboâ€controlled, doseâ€ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis and Rheumatism, 2009, 61, 1168-1178.	6.7	515
3	LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study. Arthritis and Rheumatism, 2003, 48, 442-454.	6.7	222
4	Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2014, 41, 300-309.	2.0	149
5	Longâ€ŧerm safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 3364-3373.	6.7	100
6	Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study. Journal of Rheumatology, 2013, 40, 579-589.	2.0	87
7	Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial. Journal of Rheumatology, 2012, 39, 1632-1640.	2.0	80
8	Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1125-1134.	5.6	74